Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim
Jieru Meng1, Bingliang Fang, Yong Liao
1Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America. jmeng@mdanderson.org
Abstract:
AZD6244 (ARRY-142886) is an inhibitor of MEK1/2 and can inhibit cell proliferation or induce apoptosis in a cell-type dependent manner. The precise molecular mechanism of AZD6244-induced apoptosis is not clear. To investigate mechanisms of AZD6244 induced apoptosis in human lung cancer, we determined the molecular changes of two subgroups of human lung cancer cell lines that are either sensitive or resistant to AZD6244 treatment. We found that AZD6244 elicited a large increase of Bim proteins and a smaller increase of PUMA and NOXA proteins, and induced cell death in sensitive lung cancer cell lines, but had no effect on other Bcl-2 related proteins in those cell lines. Knockdown of Bim by siRNA greatly increased the IC(50) and reduced apoptosis for AZD6244 treated cells. We also found that levels of endogenous p-Thr32-FOXO3a and p-Ser253-FOXO3a were lower in AZD6244-sensitive cells than in AZD6244-resistant cells. In the sensitive cells, AZD6244 induced FOXO3a nuclear translocation required for Bim activation. Moreover, the silencing of FOXO3a by siRNA abrogated AZD6244-induced cell apoptosis. In addition, we found that transfection of constitutively active AKT up-regulated p-Thr32-FOXO3a and p-Ser253-FOXO3a expression and inhibited AZD6244-induced Bim expression in sensitive cells. These results show that Bim plays an important role in AZD6244-induced apoptosis in lung cancer cells and that the PI3K/AKT/FOXO3a pathway is involved in Bim regulation and susceptibility of lung cancer cells to AZD6244. These results have implications in the development of strategies to overcome resistance to MEK inhibitors.
Insights
AZD6244, a MEK inhibitor, induces apoptosis in lung cancer cells primarily through the Bim protein. The PI3K/AKT/FOXO3a pathway regulates Bim, influencing sensitivity to AZD6244 and offering strategies to overcome resistance.
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- AZD6244 (ARRY-142886) is a MEK1/2 inhibitor with demonstrated effects on cell proliferation and apoptosis.
- The precise molecular mechanisms underlying AZD6244-induced apoptosis remain unclear.
- Understanding these mechanisms is crucial for developing effective lung cancer therapies.
Purpose of the Study:
- To elucidate the molecular mechanisms of AZD6244-induced apoptosis in human lung cancer.
- To compare molecular changes in AZD6244-sensitive versus resistant lung cancer cell lines.
- To identify key proteins and pathways involved in AZD6244's apoptotic effects.
Main Methods:
- Utilized sensitive and resistant human lung cancer cell lines.
- Assessed changes in Bcl-2 family proteins (Bim, PUMA, NOXA) following AZD6244 treatment.
- Employed siRNA to knockdown Bim and FOXO3a.
- Investigated the role of the PI3K/AKT/FOXO3a pathway via AKT transfection and FOXO3a phosphorylation analysis.
Main Results:
- AZD6244 significantly increased Bim protein levels and induced apoptosis in sensitive cell lines.
- Bim knockdown reduced AZD6244's efficacy, highlighting its critical role.
- AZD6244 induced FOXO3a nuclear translocation, essential for Bim activation.
- The PI3K/AKT/FOXO3a pathway modulated Bim expression and AZD6244 sensitivity.
Conclusions:
- Bim is a key mediator of AZD6244-induced apoptosis in lung cancer.
- The PI3K/AKT/FOXO3a pathway is integral to Bim regulation and AZD6244 sensitivity.
- These findings provide insights for overcoming resistance to MEK inhibitors in lung cancer treatment.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Apoptosis
Cellular Injury V: Apoptosis and Autophagy
The Extrinsic Apoptotic Pathway
Abnormal Proliferation
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...

